| 言語 |
英語
|
| 著者 |
Li Jinpeng
Department of Diabetology and Endocrinology
Liu Haijie
Department of Diabetology and Endocrinology
Takagi, Susumu
Department of Diabetology and Endocrinology
Nitta, Kyoko
Department of Diabetology and Endocrinology
Kitada, Munehiro
1Department of Diabetology and Endocrinology and 2Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Srivastava Swayam Prakash
Department of Diabetology and Endocrinology / Nephrology Section, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Takagaki, Yuta
Department of Diabetology and Endocrinology
Koya, Daisuke
1Department of Diabetology and Endocrinology and 2Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
|
| 掲載誌名 |
JCI INSIGHT
|
| 巻 | 5
|
| 号 | 6
|
| ISSN（Online） | 2379-3708
|
| 発行日 | 2020-03-26
|
| DOI | |
| PubMed ID | |
| 出版者 | AMER SOC CLINICAL INVESTIGATION INC
|
| 資料タイプ |
学術雑誌論文
|
| 部局 |
医学部
|
| 備考 | Empagliflozin was provided by Boehringer Ingelheim through a material transfer agreement. This study was essentially supported by a 2016 grant from the Japan Diabetes Foundation. This work was partially supported by the Japan Society for the Promotion of Science to KK (grants 23790381 and 23790381) and DK (grants 25282028 and 25670414). This work was partially supported by Grants for Collaborative Research awarded to DK (C2011-4 and C2012-1) and Grants for Promoted Research awarded to KK (S2015-3, S2016-3, and S20171) from Kanazawa Medical University. Boehringer Ingelheim, Mitsubishi-Tanabe Pharma, and Ono Pharmaceutical contributed to establishing the Division of Anticipatory Molecular Food Science and Technology.
|
